NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 82 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q3 2014. The put-call ratio across all filers is 179.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $217,000 | +1042.1% | 408,429 | +1921.4% | 0.00% | – |
| Q1 2016 | $19,000 | -82.7% | 20,205 | -75.6% | 0.00% | – |
| Q4 2015 | $110,000 | -1.8% | 82,716 | +67.8% | 0.00% | – |
| Q3 2015 | $112,000 | +49.3% | 49,300 | +4.6% | 0.00% | – |
| Q2 2015 | $75,000 | +158.6% | 47,137 | +153.9% | 0.00% | – |
| Q1 2015 | $29,000 | -71.8% | 18,567 | -65.8% | 0.00% | – |
| Q4 2014 | $103,000 | +505.9% | 54,307 | +297.7% | 0.00% | – |
| Q3 2014 | $17,000 | -83.5% | 13,655 | -80.4% | 0.00% | – |
| Q2 2014 | $103,000 | -51.2% | 69,579 | -38.7% | 0.00% | – |
| Q1 2014 | $211,000 | -27.0% | 113,564 | -18.6% | 0.00% | – |
| Q4 2013 | $289,000 | +94.0% | 139,518 | +148.5% | 0.00% | – |
| Q3 2013 | $149,000 | -35.2% | 56,140 | -34.9% | 0.00% | – |
| Q2 2013 | $230,000 | -51.2% | 86,194 | -50.4% | 0.00% | – |
| Q1 2013 | $471,000 | – | 173,795 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
| Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
| DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
| STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
| Hudock, Inc. | 30,500 | $63,000 | 0.05% |
| BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
| TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
| NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
| BOLTON LP | 77,400 | $160,000 | 0.03% |